JWJinghui Wang

Jinghui Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jinghui Wang has a total of 28 co-authors. Here are the top co-authors by number of shared publications:

  • Changlong Li

    Beijing Key Laboratory of Cancer Invasion and Metastasis Research, Department of Medical Genetics and Developmental Biology, School of Basic Medical Science, Capital Medical University, Beijing 100069, China

    1 shared publication
  • Daping Yu

    Department of Thoracic Surgery, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China

    1 shared publication
  • Hongxia Li

    Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China

    1 shared publication
  • Jia-Nan Gong

    Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia

    1 shared publication
  • Jianyi Lv

    School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China

    1 shared publication
  • Jing Lu

    School of Basic Medical Sciences, Capital Medical University, Beijing 100069, China

    1 shared publication

Latest Publications

  • Open Access

    Efficacy and safety of neoadjuvant chemotherapy with or without PD-L1/PD-1 inhibitors in surgically limited-stage small-cell lung cancer

    by Liang Shi, Hongxia Li, Lili Guo, Junfang Tang, Yuan Yang, Song Wei, Yujie Dong, Daping Yu, Shijie Zhou, Teng Ma, et al.

    Background: Small-cell lung cancer (SCLC) is a highly aggressive form of lung cancer. The emergence of chemoimmunotherapy has changed the mode of SCLC treatment. However, in limited-stage SCLC (LS-SCLC), the effectiveness and safety of chemoimmunotherapy in the neoadjuvant setting for LS-SCLC are not well-established. To address this gap, we conducted a study to evaluate neoadjuvant chemoimmunotherapy in LS-SCLC. Methods: A retrospective study was conducted on patients from Beijing Chest Hospital, Capital Medical University, who underwent etoposide-based chemotherapy with programmed death-ligand 1/programmed death 1 (PD-L1/PD-1) inhibitors (neoCIT group) or without (neoCT group) prior to surgery for LS-SCLC between April 2019 and March 2023. The primary endpoints were to evaluate the major pathological response (MPR) and the pathological complete response (pCR). Secondary endpoints comprised event-free survival (EFS), overall survival (OS), and safety. Results: A total of 31 patients with stage IIB-IIIB LS-SCLC were included, comprising 16 cases in the neoCIT group and 15 patients in the neoCT group. A pCR was observed in eight cases [50.0%; 95% confidence interval (CI): 28.0 to 72.0] within the neoCIT group, compared to one patient (6.7%; 95% CI: 0.3 to 29.8) in the neoCT group (odds ratio, 14.00; 95% CI: 1.71 to 164.20; P=0.02). An MPR was observed in 14 cases (87.5%; 95% CI: 64.0 to 97.8) within the neoCIT group, while three patients (20.0%; 95% CI: 7.0 to 45.2) were noted in the neoCT group, yielding an odds ratio of 28.00 (95% CI: 4.23 to 150.50; PConclusions: Our study underscores the potential of neoadjuvant chemoimmunotherapy in resectable SCLC patients. The significant improvements in pCR, MPR, EFS, and OS compared to neoadjuvant chemotherapy alone offer a promising outlook for the future management of LS-SCLC.


  • ELAVL4 promotes the tumorigenesis of small cell lung cancer by stabilizing LncRNA LYPLAL1‐DT and enhancing profilin 2 activation

    by Shuxin Li, Jianyi Lv, Xing Zhang, Qiuyu Zhang, Zhihui Li, Jing Lu, Xueyun Huo, Meng Guo, Xin Liu, Ran Gao, et al.

    Small cell lung cancer (SCLC) is one of the most malignant tumors that has an extremely poor prognosis. RNA‐binding protein (RBP) and long noncoding RNA (lncRNA) have been shown to be key regulators during tumorigenesis as well as lung tumor progression. However, the role of RBP ELAVL4 and lncRNA LYPLAL1‐DT in SCLC remains unclear. In this study, we verified that lncRNA LYPLAL1‐DT acts as an SCLC oncogenic lncRNA and was confirmed in vitro and in vivo. Mechanistically , LYPLAL1‐DT negatively regulates the expression of miR‐204‐5p, leading to the upregulation of PFN2, thus, promoting SCLC cell proliferation, migration, and invasion. ELAVL4 has been shown to enhance the stability of LYPLAL1‐DT and PFN2 mRNA. Our study reveals a regulatory pathway, where ELAVL4 stabilizes PFN2 and LYPLAL1‐DT with the latter further increasing PFN2 expression by blocking the action of miR‐204‐5p. Upregulated PFN2 ultimately promotes tumorigenesis and invasion in SCLC. These findings provide novel prognostic indicators as well as promising new therapeutic targets for SCLC.